Though it still has aims of securing a partner for phase III-ready diabetes drug sotagliflozin, Lexicon Pharmaceuticals Inc. is bolstering its balance sheet with a $50 million public offering and a concurrent $80 million convertible note offering ahead of a planned pivotal program set to start next year.